These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, Alexander Project Group. J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398 [Abstract] [Full Text] [Related]
5. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462 [Abstract] [Full Text] [Related]
6. Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Branhamella catarrhalis in children with respiratory tract infections. Varon E, Levy C, De La Rocque F, Boucherat M, Deforche D, Podglajen I, Navel M, Cohen R. Clin Infect Dis; 2000 Aug; 31(2):477-81. PubMed ID: 10987708 [Abstract] [Full Text] [Related]
9. Activity of oral beta-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance. Doern GV. Otolaryngol Head Neck Surg; 2002 Dec; 127(6 Suppl):S17-23. PubMed ID: 12511856 [Abstract] [Full Text] [Related]
10. The incidence of respiratory tract pathogens and antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated between 1990 and 1993. Nishioka K, Ogihara H, Ohno I, Tanno Y, Shirato K. Tohoku J Exp Med; 1996 Jun; 179(2):111-21. PubMed ID: 8875767 [Abstract] [Full Text] [Related]
17. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. Alpuche C, Garau J, Lim V. Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S135-8. PubMed ID: 17945468 [Abstract] [Full Text] [Related]
18. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000. Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA. Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258 [Abstract] [Full Text] [Related]